Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
I-MAB ( (IMAB) ) just unveiled an update.
On July 2, 2025, I-Mab announced positive results from a Phase 1b study of givastomig, presented at the ESMO GI 2025 in Barcelona. The study showed an 83% objective response rate in patients with gastric cancers at selected doses, demonstrating promising efficacy and safety. These results bolster I-Mab’s confidence in givastomig’s potential as a leading therapy for Claudin 18.2-positive gastric cancers, with ongoing dose expansion studies and a favorable safety profile, potentially impacting the treatment landscape for gastric cancer patients.
The most recent analyst rating on (IMAB) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on I-MAB stock, see the IMAB Stock Forecast page.
Spark’s Take on IMAB Stock
According to Spark, TipRanks’ AI Analyst, IMAB is a Neutral.
The overall stock score of 45 reflects I-MAB’s substantial financial challenges, particularly in terms of profitability and cash flow generation, which heavily impact its financial performance. Despite a modest technical uptrend, valuation metrics point to significant risks, with ongoing losses and a negative P/E ratio limiting its appeal. The absence of recent earnings call data or notable corporate events further solidifies the overall cautious outlook.
To see Spark’s full report on IMAB stock, click here.
More about I-MAB
I-Mab is a U.S.-based, global biotech company focused on the development of precision immuno-oncology agents for cancer treatment. The company’s pipeline is led by givastomig, a bispecific antibody targeting Claudin 18.2-positive gastric cancers.
Average Trading Volume: 555,363
Technical Sentiment Signal: Buy
Current Market Cap: $184.7M
Find detailed analytics on IMAB stock on TipRanks’ Stock Analysis page.